Director/PDMR Shareholding

RNS Number : 3828D

AstraZeneca PLC

19 February 2020

 

19 February 2020 07:00 GMT

TRANSACTION BY PERSON DISCHARGING MANAGERIAL RESPONSIBILITIES

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announces that, on 17 February 2020, it was notified by Michel Demaré, a Non-Executive Director of the Company, that, on 17 February 2020, Mr Demaré purchased 700 Ordinary Shares of $0.25 each in the Company (Shares) at a price of £73.13 per Share.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michel Demaré
2	Reason for the notification
a)	Position/status	Non-Executive Director
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	AstraZeneca PLC
b)	LEI	PY6ZZQWO2IZFZC3IOL08
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument Identification code	Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292
b)	Nature of the transaction	Share purchase
c)	Price(s) and volume(s)	Price(s) Volume(s) GB£73.13 700
d)	Aggregated information - Aggregated volume - Price	Not applicable - single transaction
e)	Date of the transaction	17 February 2020
f)	Place of the transaction	XLON

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com   and follow us on Twitter @ AstraZeneca .

Media Relations
Gonzalo Viña		[phone]
Rob Skelding	Oncology	[phone]
Rebecca Einhorn	Oncology	[phone]
Matt Kent	BioPharmaceuticals	[phone]
Jennifer Hursit	Other	[phone]
Christina Malmberg Hägerstrand	Sweden	[phone]
Michele Meixell	US	[phone]
Investor Relations
Thomas Kudsk Larsen		[phone]
Henry Wheeler	Oncology	[phone]
Christer Gruvris	BioPharmaceuticals (cardiovascular; metabolism)	[phone]
Nick Stone	BioPharmaceuticals (respiratory; renal)	[phone]
Josie Afolabi	Other medicines	[phone]
Craig Marks	Finance, fixed income	[phone]
Jennifer Kretzmann	Corporate access, retail investors	[phone]
US toll-free		[phone]

Adrian Kemp
Company Secretary
AstraZeneca PLC

 

END

 

 

DSHUWSVRRAUUAAR